Increased global integration in the brain after psilocybin therapy for depression

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Psilocybin shows antidepressant potential, but its mechanism is unclear.
• Understanding psilocybin's effects on brain function is crucial for depression treatment.

Purpose of the Study:

• To investigate the subacute effects of psilocybin on brain function in patients with depression.
• To compare the impact of psilocybin therapy versus escitalopram on brain network organization and antidepressant response.

Main Methods:

• Two clinical trials were conducted: an open-label trial for treatment-resistant depression and a Phase II randomized controlled trial comparing psilocybin with escitalopram.
• Functional magnetic resonance imaging (fMRI) was used to assess brain network modularity and integration at baseline and post-treatment.
• Antidepressant response was measured using the Beck Depression Inventory.

Main Results:

• Psilocybin therapy demonstrated a rapid and sustained antidepressant response, correlated with decreased brain network modularity and increased global integration.
• Functional networks rich in 5-HT2A receptors showed increased interconnectivity and flexibility after psilocybin treatment.
• Escitalopram yielded a milder antidepressant response with no significant changes in brain network organization.

Conclusions:

• Psilocybin therapy's antidepressant action may stem from a global increase in brain network integration.
• These findings suggest a distinct neurobiological mechanism for psilocybin therapy compared to conventional antidepressants.
• Consistent efficacy-related brain changes support psilocybin's potential as a novel depression treatment.